Inhibitory effect of Atorvastatin on the secretion of extracellular virulence products by Methicillin resistant Staphylococcus aureus

  • Fraidoon Abdulqader Salih Deparemrnt of Biology, College of Science, Salahaddin University – Erbil, Kurdistan Region, Iraq.
Keywords: MRSA, Atorvastatin, Haemolysin, α-Toxin, COVID-19, ACE2


       Statins are lipid-lowering therapeutic agents that have displayed useful anti-inflammatory and antibacterial properties.  The focus of this research study was to understand the role of statins in controlling bacterial pathogenicity.   Haemolysins and some other substances secreted by S. aureus were inhibited by Atorvastatin. It was found that Atorvastatin had a negligible effect on the growth of the bacteria at subminimal inhibitory concentrations, meanwhile it significantly reduced the secretion of haemolysins, coagulase and catalase. Thus, Atorvastatin could be used in conjunction with some antibiotics in controlling Methicillin resistant S. aureus MRSA infections and immunomodulation of the defense system.


Download data is not yet available.


Adhikari, R.P., Novick, R.P., 2005. Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion. Microbiology, 151, 3059–3069.
Altenbern, R.A., 1977. Extreme Sensitivity of Staphylococcal Enterotoxin B and C Production to Inhibition by Cerulenin. Antimicrob. Agents Chemother. 11, 906–908.
Berkeley, R.C.W., Pepper, E.A., Caulfield, M.P., Melling, J., 1987. The inhibition of Staphylococcus aureus enterotoxin a production by cerulenin and quinacrine; presumptive evidence for a lipid intermediate/protease release mechanism. FEMS Microbiol. Lett. 40, 103–105.
Castiglione, V., Chiriacò, M., Emdin, M., Taddei, S., Vergaro, G., 2020. Statin therapy in COVID-19 infection. Eur. Heart J. — Cardiovasc. Pharmacother.
Caulfield, M.P., Berkeley, R.C., Pepper, E.A., Melling, J., 1979. Export of extracellular levansucrase by Bacillus subtilis: inhibition by cerulenin and quinacrine. J. Bacteriol. 138, 345–351.
Cauz, A.C.G., Carretero, G.P.B., Saraiva, G.K.V., Park, P., Mortara, L., Cuccovia, I.M., Brocchi, M., Gueiros-Filho, F.J., 2019. Violacein Targets the Cytoplasmic Membrane of Bacteria. ACS Infect. Dis. 5, 539–549.
Chung, P.Y., 2020. Novel targets of pentacyclic triterpenoids in Staphylococcus aureus: A systematic review. Phytomedicine 73, 152933.
Ciaravino, V., Kropko, M.L., Rothwell, C.E., Hovey, C.A., Theiss, J.C., 1995. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat. Res. Toxicol. 343, 95–107.
DeMars, Z., Singh, V.K., Bose, J.L., 2020. Exogenous Fatty Acids Remodel Staphylococcus aureus Lipid Composition through Fatty Acid Kinase. J. Bacteriol. 202.
Engels, W., Kamps, M.A.F., 1981. Secretion of staphylocoagulase by Staphylococcus aureus: the role of a cell-bound intermediate. Antonie Van Leeuwenhoek 47, 509–524.
Fishman, Y., Rottem, S., Citri, N., 1978. Evidence linking penicillinase formation and secretion to lipid metabolism in Bacillus licheniformis. J. Bacteriol. 134, 434–439.
Graziano, T.S., Cuzzullin, M.C., Franco, G.C., Schwartz-Filho, H.O., Andrade, E.D. de, Groppo, F.C., Cogo-Müller, K., 2015. Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm. PLOS ONE 10, e0128098.
Guerin Maryse, Lassel Taous S., Le Goff Wilfried, Farnier Michel, Chapman M. John, 2000. Action of Atorvastatin in Combined Hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 20, 189–197.
Hennessy, E., Adams, C., Reen, F.J., O’Gara, F., 2016. Is There Potential for Repurposing Statins as Novel Antimicrobials? Antimicrob. Agents Chemother. 60, 5111–5121.
Hiltunen, M., Söderhäll, K., 1992. Inhibition of polyketide synthesis in Alternaria alternata by the fatty acid synthesis inhibitor cerulenin. Appl. Environ. Microbiol. 58, 1043–1045.
Hirano, T., Murakami, M., 2020. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity 52, 731–733.
Horn, M.P., Knecht, S.M., Rushing, F.L., Birdsong, J., Siddall, C.P., Johnson, C.M., Abraham, T.N., Brown, A., Volk, C.B., Gammon, K., Bishop, D.L., McKillip, J.L., McDowell, S.A., 2008. Simvastatin Inhibits Staphylococcus aureus Host Cell Invasion through Modulation of Isoprenoid Intermediates. J. Pharmacol. Exp. Ther. 326, 135–143.
Jacques, N.A., 1983. Membrane Perturbation by Cerulenin Modulates Glucosyltransferase Secretion and Acetate Uptake by Streptococcus salivarius. Microbiology, 129, 3293–3302.
Khan, A., Wilson, B., Gould, I.M., 2018. Current and future treatment options for community-associated MRSA infection. Expert Opin. Pharmacother. 19, 457–470.
Khan, T.J., Ahmed, Y.M., Zamzami, M.A., Mohamed, S.A., Khan, I., Baothman, O.A.S., Mehanna, M.G., Yasir, M., 2018. Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats. Sci. Rep. 8, 662.
Ko, H.H.T., Lareu, R.R., Dix, B.R., Hughes, J.D., 2017. Statins: antimicrobial resistance breakers or makers? PeerJ 5, e3952.
Lakhundi, S., Zhang, K., 2018. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin. Microbiol. Rev. 31.
Liu, C.-I., Liu, G.Y., Song, Y., Yin, F., Hensler, M.E., Jeng, W.-Y., Nizet, V., Wang, A.H.-J., Oldfield, E., 2008. A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence. Science 319, 1391–1394.
Liu, G.Y., Essex, A., Buchanan, J.T., Datta, V., Hoffman, H.M., Bastian, J.F., Fierer, J., Nizet, V., 2005. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 202, 209–215.
Manalo, R.V.M., Josol, V.J.D., Gloriani, N.G., 2017. The differential effects of atorvastatin co-administered with ampicillin on the bacterial growth and biofilm formation of Staphylococcus aureus. Curr. Med. Res. Pract. 7, 178–183.
MÄntsälä, P., 1982. Inhibition of Protein Secretion by Cerulenin in Bacillus subtilis. Microbiology, 128, 2967–2972.
Naimi, T.S., 2003. Comparison of Community- and Health Care–Associated Methicillin-Resistant Staphylococcus aureus Infection. JAMA 290, 2976.
PATON, J.C., MAY, B.K., ELLIOTT, W.H., 1980. Cerulenin Inhibits Production of Extracellular Proteins but not Membrane Proteins in Bacillus amyloliquefaciens. Microbiology, 118, 179–187.
Petit‐Glatron, M.-F., Chambert, R., 1981. Levansucrase of Bacillus subtilis: Conclusive Evidence that Its Production and Export are Unrelated to Fatty-Acid Synthesis but Modulated by membrane-Modifying Agents. Eur. J. Biochem. 119, 603–611.
Price, A.C., Choi, K.-H., Heath, R.J., Li, Z., White, S.W., Rock, C.O., 2001. Inhibition of β-Ketoacyl-Acyl Carrier Protein Synthases by Thiolactomycin and Cerulenin STRUCTURE AND MECHANISM. J. Biol. Chem. 276, 6551–6559.
Pruefer Diethard, Scalia Rosario, Lefer Allan M., 1999. Simvastatin Inhibits Leukocyte–Endothelial Cell Interactions and Protects Against Inflammatory Processes in Normocholesterolemic Rats. Arterioscler. Thromb. Vasc. Biol. 19, 2894–2900.
Ragia, G., Manolopoulos, V.G., 2020. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur. J. Clin. Pharmacol. 1–8.
Rana, R., Sharma, R., Kumar, A., 2019. Repurposing of Existing Statin Drugs for Treatment of Microbial Infections: How Much Promising? Infect. Disord. - Drug TargetsDisorders 19, 224–237.
Saleh, F.A.K., Freer, J.H., 1984. Inhibition of Secretion of Staphylococcal Alph Toxin by Cerulenin. J. Med. Microbiol. 18, 205–216.
Sarkeshikian, S.S., Ghadir, M.R., Alemi, F., Jalali, S.M., Hormati, A., Mohammadbeigi, A., 2020. Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial. J. Gastroenterol. Hepatol. 35, 71–75.
Siddiqui, A.H., Koirala, J., 2020. Methicillin Resistant Staphylococcus Aureus, in: StatPearls. StatPearls Publishing, Treasure Island (FL).
Silhavy, T.J., Benson, S.A., Emr, S.D., 1983. Mechanisms of protein localization. Microbiol. Rev. 47, 313–344.
Wang, J., Ye, X., Yang, X., Cai, Y., Wang, S., Tang, J., Sachdeva, M., Qian, Y., Hu, W., Leeds, J.A., Yuan, Y., 2020. Discovery of Novel Antibiotics as Covalent Inhibitors of Fatty Acid Synthesis. ACS Chem. Biol. 15, 1826–1834.
Welsh, A.-M., Kruger, P., Faoagali, J., 2009. Antimicrobial action of atorvastatin and rosuvastatin. Pathology (Phila.) 41, 689–691.
Zhang, X.-J., Qin, J.-J., Cheng, X., Shen, L., Zhao, Y.-C., Yuan, Y., Lei, F., Chen, M.-M., Yang, H., Bai, L., Song, X., Lin, L., Xia, M., Zhou, F., Zhou, J., She, Z.-G., Zhu, L., Ma, X., Xu, Q., Ye, P., Chen, G., Liu, L., Mao, W., Yan, Y., Xiao, B., Lu, Z., Peng, G., Liu, M., Yang, Jun, Yang, L., Zhang, C., Lu, H., Xia, X., Wang, D., Liao, X., Wei, X., Zhang, B.-H., Zhang, X., Yang, Juan, Zhao, G.-N., Zhang, P., Liu, P.P., Loomba, R., Ji, Y.-X., Xia, J., Wang, Y., Cai, J., Guo, J., Li, H., 2020. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 32, 176-187.e4.
How to Cite
Salih, F. (2021) “Inhibitory effect of Atorvastatin on the secretion of extracellular virulence products by Methicillin resistant Staphylococcus aureus”, Zanco Journal of Pure and Applied Sciences, 33(4), pp. 82-89. doi: 10.21271/ZJPAS.33.4.8.
Biology and Medical Researches